EPCORE PEDS-1 (Epcoritamap)

A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients with Relapsed/ Refractory Aggressive Mature B-cell Neoplasms.



The purpose of this study is to assess the safety and tolerability of epcoritamab monotherapy in pediatric patients with relapsed/refractory aggressive mature B-cell neoplasms and young adult patients with Burkitt's or Burkitt-like lymphoma/leukemia. 

Epcoritamab is a bispecific antibody that binds CD3 on T cells and CD20 on B cells, inducing potent and selective T-cell-mediated killing of malignant CD20+ B cells. Patients will receive subcutaneous epcoritamab in 28-day cycles and will be followed for a minimum of 3 years after enrollment.

Main inclusion criteria

  • Age: ≥ 1 to < 18 years at time of primary diagnosis
  • Diagnosis with relapsed/refractory:
    • Burkitt's or Burkitt-like lymphoma/leukemia,
    • Diffuse large B-cell lymphoma (DLBCL), 
    • or other aggressive mature (CD20+) B-cell lymphomas


AbbVie Germany

Diese Webseite verwendet Cookies. Durch die Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Datenschutzinformationen